This research finds 1'-acetoxychavicol acetate reduces cancer cell proliferation and migration in colorectal cancer, suggesting therapeutic potential.
Cancer is a significant cause of mortality worldwide, including in Thailand. However, chemotherapy has serious side effects. Ongoing research on the compound 1'-acetoxychavicol acetate (ACA) has revealed various medicinal properties, including anticancer and anti-inflammatory activities. Although ACA has been found to affect cancer cell lines through different mechanisms, few reports have focused on its effectiveness against colorectal cancer cell lines. This research aims to determine the anticancer activities of ACA on the SW620 cell line. Anticancer activities, including anti-proliferation, anti-migration, and anti-invasion, were evaluated using methylthiazolyldiphenyl-tetrazolium bromide (MTT), colony formation, scratch assays, invasion assays, and qRT-PCR. The results showed that ACA exhibited cytotoxic effects (IC50 values) and anti-proliferative activity in a dose-dependent manner. ACA also demonstrated anti-migration and anti-invasion activities in a dose-dependent manner. Additionally, the qRT-PCR results showed that ACA significantly decreased Kirsten rat sarcoma viral oncogene homolog (KRAS) gene expressions compared to the control group. ACA exhibits anti-proliferative, anti-migratory, and anti-invasive activities in SW620 cells. These findings suggest the potential of ACA as a therapeutic agent and may provide insights that significantly advance our understanding of cancer biology and treatment.
No takes yet. Share an insight, caveat, or question.
Ketkomol et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: